Watts Gwilliam & Co. LLC Has $1.92 Million Stock Holdings in Pfizer Inc. $PFE

Watts Gwilliam & Co. LLC grew its position in Pfizer Inc. (NYSE:PFE) by 176.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 79,423 shares of the biopharmaceutical company’s stock after buying an additional 50,744 shares during the period. Watts Gwilliam & Co. LLC’s holdings in Pfizer were worth $1,918,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new stake in Pfizer in the second quarter worth about $2,270,157,000. Amundi lifted its position in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Pfizer by 43.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after purchasing an additional 5,662,309 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after buying an additional 3,943,397 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.2%

Shares of Pfizer stock opened at $25.86 on Monday. The company has a market capitalization of $147.04 billion, a P/E ratio of 15.04 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business has a 50-day moving average of $25.12 and a two-hundred day moving average of $24.78. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 100.00%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on PFE shares. HSBC restated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a report on Wednesday. Citigroup started coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Guggenheim boosted their target price on Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.22.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.